Genmab (GMAB)
(Real Time Quote from BATS)
$28.02 USD
-0.06 (-0.21%)
Updated Sep 18, 2025 11:44 AM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Genmab A/S Sponsored ADR has a PEG ratio of 1.61 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.64.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GMAB 28.02 -0.06(-0.21%)
Will GMAB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for GMAB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GMAB
IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi
Wall Street Analysts Believe Genmab (GMAB) Could Rally 33.8%: Here's is How to Trade
GMAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
NVAX Stock Gains on Q2 Earnings & Sales Beat, Ups '25 Sales View
Perrigo Beats on Q2 Earnings & Sales, Stock Down on '25 Sales View Cut
JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut
Other News for GMAB
GMAB's price falls by 0.57% on September 17, though its technical setup remains stable.
GMAB forms NR7 on September 16
GMAB forms Pocket Pivot on September 15
Genmab Transitioning To A Global Oncology Powerhouse: Why I Choose To Buy
Is GMAB likely to continue higher? Slingshot Bullish shows up after slipping 2.76%